ATE521715T1 - Substrate für beta-lactamase und deren verwendung - Google Patents

Substrate für beta-lactamase und deren verwendung

Info

Publication number
ATE521715T1
ATE521715T1 AT03025361T AT03025361T ATE521715T1 AT E521715 T1 ATE521715 T1 AT E521715T1 AT 03025361 T AT03025361 T AT 03025361T AT 03025361 T AT03025361 T AT 03025361T AT E521715 T1 ATE521715 T1 AT E521715T1
Authority
AT
Austria
Prior art keywords
beta
group
lactamase
substrates
chr
Prior art date
Application number
AT03025361T
Other languages
English (en)
Inventor
Roger Y Tsien
Gregor Zlokarnik
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE521715T1 publication Critical patent/ATE521715T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/36—Methylene radicals, substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
    • C12P17/184—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system containing a beta-lactam ring, e.g. thienamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/986—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides (3.5.2), e.g. beta-lactamase (penicillinase, 3.5.2.6), creatinine amidohydrolase (creatininase, EC 3.5.2.10), N-methylhydantoinase (3.5.2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2415/00—Assays, e.g. immunoassays or enzyme assays, involving penicillins or cephalosporins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/805—Test papers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Cephalosporin Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AT03025361T 1995-03-20 1996-03-20 Substrate für beta-lactamase und deren verwendung ATE521715T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/407,544 US5741657A (en) 1995-03-20 1995-03-20 Fluorogenic substrates for β-lactamase and methods of use

Publications (1)

Publication Number Publication Date
ATE521715T1 true ATE521715T1 (de) 2011-09-15

Family

ID=23612529

Family Applications (3)

Application Number Title Priority Date Filing Date
AT03025361T ATE521715T1 (de) 1995-03-20 1996-03-20 Substrate für beta-lactamase und deren verwendung
AT99118473T ATE253632T1 (de) 1995-03-20 1996-03-20 Nukleinsäuren und deren verwendung zur bestimmung von beta-laktamase
AT96912454T ATE200287T1 (de) 1995-03-20 1996-03-20 Substrate für beta-lactamase und deren verwendung

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT99118473T ATE253632T1 (de) 1995-03-20 1996-03-20 Nukleinsäuren und deren verwendung zur bestimmung von beta-laktamase
AT96912454T ATE200287T1 (de) 1995-03-20 1996-03-20 Substrate für beta-lactamase und deren verwendung

Country Status (13)

Country Link
US (5) US5741657A (de)
EP (3) EP1405922B1 (de)
JP (2) JP3633940B2 (de)
CN (2) CN1066731C (de)
AT (3) ATE521715T1 (de)
AU (1) AU723164B2 (de)
CA (1) CA2215310C (de)
DE (2) DE69630622T2 (de)
DK (2) DK0982398T3 (de)
ES (2) ES2156994T3 (de)
MX (1) MX9707213A (de)
PT (1) PT982398E (de)
WO (1) WO1996030540A2 (de)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US6821727B1 (en) 1993-11-15 2004-11-23 Applera Corporation Hybridization assay using self-quenching fluorescence probe
US7427680B2 (en) * 2001-01-12 2008-09-23 The Regents Of The University Of California Fluorogenic substrates for BETA-lactamase gene expression
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US20070020715A1 (en) * 1995-03-20 2007-01-25 The Regents Of The University Of California Novel fluorogenic substrates for beta-lactamase gene expression
US20040157262A1 (en) * 1996-04-30 2004-08-12 Michel Kohl Conjugates of haptens to beta-lactam derivatives and their use for detecting and/or quantifying haptens in solution and device for implementation thereof
US7388092B2 (en) * 1996-05-03 2008-06-17 Applera Corporation Oligonucleotides and analogs labeled with energy transfer dyes
US7825237B2 (en) * 1996-05-03 2010-11-02 Applied Biosystems, Llc Oligonucleotides and analogs labeled with energy transfer dyes
US5800996A (en) * 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5945526A (en) * 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US6004808A (en) * 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
US6593135B2 (en) * 1996-08-16 2003-07-15 The State Of Oregon, Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Long wavelength engineered fluorescent proteins
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
US5928888A (en) * 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
FI963989L (fi) * 1996-10-04 1998-04-05 Wallac Oy Homogeenisiä määritysmenetelmiä, jotka perustuvat luminesenssienergiasiirtoon
US5955604A (en) * 1996-10-15 1999-09-21 The Regents Of The University Of California Substrates for β-lactamase and uses thereof
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
DE19717904A1 (de) * 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
CN1254383A (zh) * 1997-05-01 2000-05-24 美国3M公司 基于染料二聚作用的生荧光蛋白水解酶底物
US6214563B1 (en) * 1997-08-01 2001-04-10 Aurora Biosciences Corporation Photon reducing agents for reducing undesired light emission in assays
US6221612B1 (en) 1997-08-01 2001-04-24 Aurora Biosciences Corporation Photon reducing agents for use in fluorescence assays
US6200762B1 (en) * 1997-08-01 2001-03-13 Aurora Biosciences Corporation Photon reducing agents and compositions for fluorescence assays
US6689574B1 (en) 1997-10-07 2004-02-10 Merck & Co., Inc. Assays for nuclear receptor agonists and antagonists using fluorescence resonance energy transfer
WO1999040114A1 (en) * 1998-02-05 1999-08-12 Merck & Co., Inc. Novel gabab receptor dna sequences
US6284461B1 (en) 1998-04-28 2001-09-04 Aurora Biosciences Corporation Use of inhibitors in reporter assays
US6031094A (en) * 1998-07-23 2000-02-29 The Regents Of The University Of California Beta-lactam substrates and uses thereof
US6051395A (en) * 1998-08-25 2000-04-18 Biometric Imaging, Inc. Method and compound for detecting low levels of microorganisms
US6420130B1 (en) 1998-12-14 2002-07-16 Aurora Biosciences Corporation Optical molecular sensors for cytochrome P450 activity
US6514687B1 (en) * 1998-12-14 2003-02-04 Vertex Pharmaceuticals (San Diego), Llc Optical molecular sensors for cytochrome P450 activity
CA2352631A1 (en) * 1998-12-14 2000-06-22 Life Technologies Corporation Optical molecular sensors for cytochrome p450 activity
US6143492A (en) * 1998-12-14 2000-11-07 Aurora Biosciences Corporation Optical molecular sensors for cytochrome P450 activity
US8148110B2 (en) * 1999-03-15 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by β-lactamase reporter fragment complementation
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
CA2374476A1 (en) * 1999-05-25 2000-11-30 Panorama Research, Inc. Interaction-activated proteins
US6218124B1 (en) 1999-08-27 2001-04-17 Pe Corporation Method for detecting oligonucleotides using UV light source
US6358684B1 (en) 1999-08-27 2002-03-19 Pe Corporation UV excitable fluorescent energy transfer dyes
AU3642701A (en) 1999-11-05 2001-05-30 Iconix Pharmaceuticals, Inc. Hydrolytic enzyme substrates and assay method
US20040072739A1 (en) * 1999-11-10 2004-04-15 Anderson Christen M. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
US6692965B1 (en) * 1999-11-23 2004-02-17 Chromocell Corporation Isolation of living cells and preparation of cell lines based on detection and quantification of preselected cellular ribonucleic acid sequences
EP1248840A2 (de) 2000-01-13 2002-10-16 Panorama Research, Inc. Zirkulärpermutierte, wechselwirkungsaktive proteine
EP1254179A4 (de) 2000-01-24 2005-06-01 Univ Columbia In vivo screen unter verwendung von chemischen induktoren
US7262005B1 (en) 2000-02-04 2007-08-28 Aurora Biosciences Corporation Methods of protein destabilization and uses thereof
DE60143192D1 (de) 2000-02-08 2010-11-18 Sangamo Biosciences Inc Zellen zur entdeckung von medikamenten
US7029868B2 (en) * 2000-02-17 2006-04-18 Merck & Co., Inc. Cell fusion assays using fluorescence resonance energy transfer
ATE439441T1 (de) * 2000-02-23 2009-08-15 Life Technologies Corp Veränderte, fluoreszierende proteine
EP1143013A1 (de) 2000-04-03 2001-10-10 Warner-Lambert Company Verfahren und Zusammenzetzungen zur Screening von ICRAC-Modulatoren
EP1143017A3 (de) * 2000-04-03 2004-01-28 Warner-Lambert Company LLC Methoden und Zusammensetzungen zum Screenen von icrac Modulatoren
US6806289B1 (en) 2000-07-14 2004-10-19 Stephen J. Lippard Coordination complexes, and methods for preparing by combinatorial methods, assaying and using the same
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
JP2005501806A (ja) * 2001-01-12 2005-01-20 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア フェノール性エーテルを有する、β−ラクタマーゼの基質
US6850317B2 (en) * 2001-01-23 2005-02-01 Schlumberger Technology Corporation Apparatus and methods for determining velocity of oil in a flow stream
US7142306B2 (en) * 2001-01-23 2006-11-28 Schlumberger Technology Corporation Optical probes and probe systems for monitoring fluid flow in a well
US7005511B2 (en) 2001-02-26 2006-02-28 The Regents Of The University Of California Fluorescent protein variants and methods for making same
JP2004532012A (ja) * 2001-03-02 2004-10-21 メルク　エンド　カムパニー　インコーポレーテッド ウイルスリポーター粒子
EP1425065A4 (de) * 2001-07-12 2004-12-15 Merck & Co Inc Elektrische feldstimulation mit eukaryontischen zellen
US20030104604A1 (en) * 2001-08-03 2003-06-05 Weiping Yang Genetically engineered bacterial strains for the display of foreign peptides on filamentous phage
US6696473B2 (en) * 2001-12-21 2004-02-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) * 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US20050181464A1 (en) * 2002-04-04 2005-08-18 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from bacteria
ES2197811B2 (es) * 2002-04-05 2005-05-01 Universidad Complutense De Madrid Sintesis de derivados fluorescentes de antiobioticos beta-lactamicos.
CA2481171A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Hepatitis c virus assay systems
US7083918B2 (en) 2002-04-24 2006-08-01 The Trustees Of Columbia University In The City Of New York Bacterial small-molecule three-hybrid system
AU2003245755A1 (en) * 2002-06-28 2004-01-19 Genepharm, Inc. A method to identify specific interaction between ligand and receptor
US20040219516A1 (en) * 2002-07-18 2004-11-04 Invitrogen Corporation Viral vectors containing recombination sites
ATE425261T1 (de) * 2002-10-29 2009-03-15 Showa Pharm Chem Ind Reagenzzusammensetzung, kit und verfahren zur unterscheidung von beta-lactamasen
AU2003291287A1 (en) 2002-11-01 2004-06-07 John Fonda Crary Apkc isoforms in nervous system disorders and cancer
JP4634371B2 (ja) 2003-03-27 2011-02-16 ピーティーシー セラピューティクス，インコーポレーテッド ｔＲＮＡスプライシングエンドヌクレアーゼに標的化する化合物の同定方法、および該化合物の抗増殖剤としての使用
WO2004087884A2 (en) 2003-03-27 2004-10-14 Ptc Therapeutics, Inc TARGETING ENZYMES OF THE tRNA SPLICING PATHWAY FOR IDENTIFICATION OF ANTI-FUNGAL AND/OR ANTI-PROLIFERATIVE MOLECULES
US7323303B2 (en) * 2003-03-31 2008-01-29 Hong Kong Polytechnic University Modified β-lactamases and uses thereof
US7473548B2 (en) 2003-04-25 2009-01-06 Medtronic, Inc. Optical detector for enzyme activation
WO2004098764A2 (en) 2003-04-30 2004-11-18 Aurora Discovery, Inc. Multi-well plate providing a high-density storage and assay platform
US7399639B2 (en) * 2003-05-04 2008-07-15 Massachusetts Institute Of Technology Sensors, and methods of making and using the same
GB0311948D0 (en) * 2003-05-23 2003-06-25 Stockport Innovation Ltd Light emitting probes
US20050095615A1 (en) * 2003-06-26 2005-05-05 Welch Peter J. Methods and compositions for detecting promoter activity and expressing fusion proteins
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US20050069929A1 (en) 2003-08-08 2005-03-31 Invitrogen Corporation Methods and compositions for seamless cloning of nucleic acid molecules
US7304168B2 (en) * 2003-08-14 2007-12-04 Board Of Regents, University Of Texas System Photo-caged fluorescent molecules
US8304189B2 (en) 2003-12-01 2012-11-06 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
WO2005059167A1 (en) * 2003-12-18 2005-06-30 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for identifying histone deacetylase inhibitors
WO2005071096A2 (en) * 2004-01-21 2005-08-04 Molecular Probes, Inc. Derivatives of cephalosporin and clavulanic acid for detecting beta-lacamase in a sample
KR20150005720A (ko) * 2004-02-18 2015-01-14 크로모셀 코포레이션 신호 프로브를 이용하는 방법 및 물질
KR100663038B1 (ko) 2004-07-22 2007-01-02 학교법인 명지학원 외부유전자의 발현 및 단백질의 분비를 위한 벡터 ｐＭＳＧ1220
WO2007002563A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
FR2889700B1 (fr) * 2005-08-11 2012-11-23 Synthinnove Lab Marqueurs, leur procede de fabrication et leurs applications
DE102005044071A1 (de) * 2005-09-07 2007-03-08 Nimbus Biotechnologie Gmbh Verfahren zur Messung der Permeation einer Substanz durch eine Barriere
WO2007100392A2 (en) * 2005-11-30 2007-09-07 Biotium, Inc. Enzyme substrate comprising a functional dye and associated technology and methods
CN100487435C (zh) * 2005-12-22 2009-05-13 云南农业大学 一种松树萎蔫病病原线虫的检测方法
US20070218456A1 (en) * 2006-02-08 2007-09-20 Invitrogen Corporation Cellular assays for signaling receptors
NZ579010A (en) * 2007-02-20 2012-03-30 Anaptysbio Inc Somatic hypermutation systems
US20110065595A1 (en) * 2007-04-12 2011-03-17 Nathan Citri Method and Test Kit for the Rapid Identification and Characterization of Cells
JP5628677B2 (ja) 2007-10-19 2014-11-19 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ ベータ−ラクタマーゼの検出のための方法および組成物
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
US7867758B2 (en) * 2008-04-01 2011-01-11 The Board Of Trustees Of The Leland Stanford Junior University Bioluminogenic assay system for measuring beta-lactamase activity
US9828622B2 (en) 2008-05-05 2017-11-28 The General Hospital Corporation Photoactivatable antimicrobial agents and therapeutic and diagnostic methods of using same
CN102369440B (zh) * 2008-08-06 2016-02-17 得克萨斯A&M大学体系 细菌β-内酰胺酶在体外诊断与体内成像、诊断和治疗中的应用
US9834807B2 (en) 2008-10-20 2017-12-05 Becton, Dickinson And Company Compositions for the detection of intracellular bacterial targets and other intracellular micororganism targets
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
CA2747244A1 (en) 2008-12-12 2010-06-17 University Of Florida Research Foundation, Inc. Cell-based detection of apf through its interaction with ckap4 for diagnosis of interstitial cystitis
US8431416B2 (en) 2009-04-01 2013-04-30 Becton, Dickinson And Company Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates
WO2010113039A1 (en) 2009-04-03 2010-10-07 Medical Research Council Mutants of activation-induced cytidine deaminase (aid) and methods of use
AU2010245860B2 (en) * 2009-05-07 2015-07-16 Biomerieux, Inc. Methods for antimicrobial resistance determination
US9400273B1 (en) 2009-12-09 2016-07-26 Life Technologies Corporation 7-hydroxycoumarin-based cell-tracking reagents
US8318953B2 (en) * 2010-06-23 2012-11-27 Aat Bioquest, Inc. Reactive coumarin derivatives and their use in cellular analyses
CN102115780B (zh) * 2010-12-15 2013-01-30 黑龙江省乳品工业技术开发中心 一种检测β-内酰胺酶的试剂盒及其制备和检测方法
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
WO2013053953A1 (en) * 2011-10-14 2013-04-18 Université de Liège Method for measuring beta-lactam antibiotics
CN103509083B (zh) * 2012-06-28 2016-06-08 王郁生 一种广谱β-内酰胺酶荧光底物及其制备方法和应用
KR102055438B1 (ko) 2012-07-31 2019-12-19 에이지엑스 쎄라퓨틱스, 인크. Hla g-변형된 세포 및 방법
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3183580B1 (de) 2014-08-21 2025-03-26 Eurofins DiscoverX Corporation Homogener thermal-shift-ligandenbindungstest
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
US20180021364A1 (en) 2015-01-16 2018-01-25 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
CN104714006B (zh) * 2015-02-04 2017-10-20 国家纳米科学中心 一种检测奶制品中β‑内酰胺酶的方法
EP3368054A4 (de) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. Regulierbare expression unter verwendung des adeno-assoziierten virus (aav)
WO2017096162A1 (en) 2015-12-02 2017-06-08 Voyager Therapeutics, Inc. Assays for the detection of aav neutralizing antibodies
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR20220108216A (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
CN110650673B (zh) 2016-08-30 2024-04-09 加利福尼亚大学董事会 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
CN108623617B (zh) * 2017-03-22 2021-04-02 蒋辉 一种头孢噻呋中间体的制备方法
SG11201909870SA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
TWI832036B (zh) 2017-08-03 2024-02-11 美商航海家醫療公司 用於aav之遞送之組合物及方法
US10739331B2 (en) * 2017-08-11 2020-08-11 Bioventures, Llc OMA1 activity assay
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
EP4454654A3 (de) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Behandlung von amyotropher lateralsklerose (als)
US20210236644A1 (en) 2017-11-10 2021-08-05 Cocoon Biotech Inc. Ocular applications of silk-based products
US20210010028A1 (en) 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
US12129476B2 (en) 2018-04-27 2024-10-29 Voyager Therapeutics, Inc. Methods for measuring the potency of AADC viral vectors
WO2019222329A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
EP3794126A1 (de) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von morbus parkinson
EP3793615A2 (de) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Gerichtete entwicklung von aav zur verbesserung des tropismus für zns
EP3793686A1 (de) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Aav-serotypen zur gehirnspezifischen payload-übertragung
CN113383010B (zh) 2018-09-28 2025-09-09 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
EP3962932A4 (de) 2019-05-02 2023-05-10 Board of Regents, The University of Texas System System und verfahren zur erhöhung der stabilität von synthetisierten proteinen
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2021046155A1 (en) 2019-09-03 2021-03-11 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
BR112022020753A2 (pt) 2020-04-15 2022-12-20 Voyager Therapeutics Inc Compostos de ligação a tau
AU2021273447B2 (en) 2020-05-13 2026-03-05 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
CN111621492B (zh) * 2020-06-15 2021-10-26 安徽红杉生物医药科技有限公司 内酰胺酶及其应用和酶法拆分制备(1r，4s)-文斯内酯的方法
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
BR112023001456A2 (pt) 2020-07-27 2023-04-11 Voyager Therapeutics Inc Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
WO2022157548A1 (en) 2021-01-24 2022-07-28 Forrest Michael David Inhibitors of atp synthase - cosmetic and therapeutic uses
EP4405396A2 (de) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von her2-positivem krebs
US20250049955A1 (en) 2021-11-17 2025-02-13 Voyager Therapeutics, Inc. Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
AU2023427408A1 (en) 2023-02-02 2025-09-04 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
TW202449167A (zh) 2023-04-26 2024-12-16 美商航海家醫療公司 用於治療肌肉萎縮性脊髓側索硬化症之組成物及方法
EP4705317A1 (de) 2023-05-03 2026-03-11 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von erkrankungen im zusammenhang mit cdkl5-mangel
WO2024229173A2 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
AU2024265526A1 (en) 2023-05-03 2025-12-11 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2024229164A2 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
WO2024229167A1 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
WO2025038795A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
WO2025038796A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to cdkl5 deficiency
WO2025038802A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
WO2025038805A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2025122530A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2025122532A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
WO2025122536A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
WO2025122548A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to cdkl5 deficiency
WO2025122543A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
WO2025137219A1 (en) 2023-12-21 2025-06-26 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS563876B2 (de) * 1973-06-22 1981-01-27
JPS534810B2 (de) 1975-02-13 1978-02-21
US4234683A (en) * 1978-11-24 1980-11-18 Mcmillan William A Beta-lactamase diagnostic product and method
DE2916433A1 (de) * 1979-04-24 1980-11-13 Hoechst Ag Chromophore cephalosporine und verfahren zu ihrer herstellung
DE3019451A1 (de) * 1980-05-21 1981-11-26 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und reagens zur bestimmung von (beta) -lactamasen
FR2494279A1 (fr) * 1980-11-20 1982-05-21 Rhone Poulenc Ind Nouvelles oxacephalosporines, leur preparation et les medicaments qui les contiennent
US4740459A (en) * 1984-08-06 1988-04-26 Washington Research Foundation Fluorescence assay for microbial beta-lactamase
US4760018A (en) * 1985-06-17 1988-07-26 Penicillin Assays, Inc. Rapid method for the detection of beta-lactamase in body fluids
US4764462A (en) * 1985-08-23 1988-08-16 Georgetown University Detectably labeled cephalosporin assay for beta-lactamase
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
GB8819104D0 (en) * 1988-08-11 1988-09-14 Beecham Group Plc Novel compounds
US4978613A (en) * 1989-01-17 1990-12-18 Abbott Laboratories Beta-lactamase assay employing chromogenic precipitating substrates
EP0448650A4 (en) * 1989-02-01 1992-05-13 The General Hospital Corporation Herpes simplex virus type i expression vector
WO1991013160A1 (en) * 1990-02-28 1991-09-05 Schering Corporation Mammalian expression vectors
US5264346A (en) * 1991-06-03 1993-11-23 Chen Kirk C S Colorimetric method for beta-lactamase assay and its applications
US5162524B1 (en) * 1991-06-06 1997-06-17 Bristol Myers Squibb Co Processes for making cephems from allenylazetidinone derivatives
US5639596A (en) * 1991-08-16 1997-06-17 Gsf-Forschungszentrum Fur Umweltund Gesundheit DNA construct and in vitro test for detecting tumor promoters by means of said DNA construct
US5356797A (en) * 1991-11-15 1994-10-18 Board Of Regents, The University Of Texas Membrane expression of heterologous genes
US5338843A (en) * 1992-01-30 1994-08-16 Becton, Dickinson And Company Fluorogenic and chromogenic β-lactamase substrates
US5593866A (en) * 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
US5741657A (en) * 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
GB9523703D0 (en) * 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
US5955604A (en) * 1996-10-15 1999-09-21 The Regents Of The University Of California Substrates for β-lactamase and uses thereof

Also Published As

Publication number Publication date
ATE253632T1 (de) 2003-11-15
DE69612375T2 (de) 2001-10-31
EP1405922B1 (de) 2011-08-24
EP0817785B1 (de) 2001-04-04
EP0982398B1 (de) 2003-11-05
ATE200287T1 (de) 2001-04-15
EP0982398A1 (de) 2000-03-01
DE69630622D1 (de) 2003-12-11
US8071761B2 (en) 2011-12-06
EP0817785A2 (de) 1998-01-14
EP1405922A3 (de) 2004-09-29
JP3856807B2 (ja) 2006-12-13
US7157575B2 (en) 2007-01-02
DE69630622T2 (de) 2004-09-23
DK0982398T3 (da) 2004-02-16
US20030119085A1 (en) 2003-06-26
ES2156994T3 (es) 2001-08-01
JPH11502714A (ja) 1999-03-09
DK0817785T3 (da) 2001-07-02
JP2005021172A (ja) 2005-01-27
PT982398E (pt) 2004-02-27
AU723164B2 (en) 2000-08-17
AU5526696A (en) 1996-10-16
WO1996030540A3 (en) 1997-01-09
CA2215310C (en) 2002-05-21
CN1213144C (zh) 2005-08-03
MX9707213A (es) 1998-07-31
US6291162B1 (en) 2001-09-18
CA2215310A1 (en) 1996-10-03
US5741657A (en) 1998-04-21
US6472205B1 (en) 2002-10-29
CN1066731C (zh) 2001-06-06
CN1296078A (zh) 2001-05-23
DE69612375D1 (de) 2001-05-10
US20070184513A1 (en) 2007-08-09
EP1405922A2 (de) 2004-04-07
CN1184479A (zh) 1998-06-10
WO1996030540A2 (en) 1996-10-03
ES2209305T3 (es) 2004-06-16
JP3633940B2 (ja) 2005-03-30

Similar Documents

Publication Publication Date Title
ATE200287T1 (de) Substrate für beta-lactamase und deren verwendung
EP0767382A3 (de) Fluoreszierende Verbindungen und deren Verwendung zum Messen von Reticulozyten
HU9502811D0 (en) N-acyl-sulfamic acid esters (or thioesters), n-acyl-sulfonamides and n-sulfonyl-carbamic-acid-esters (or thioesters) as hypercholesterolemic agents
ATE132156T1 (de) Latente carbamat-silizium-haftvermittler und verfahren zu deren herstellung und verwendung
PE43597A1 (es) Procedimiento y derivados de n-(3-benzofuranil)urea
GB9815163D0 (en) Compounds
CA2009925A1 (en) Method for enhancement of chemiluminescence
TR199701700T1 (xx) Bile�imler ve bu bile�imleri i�eren farmas�tik terkipler
WO1996031531A3 (en) Fluorescent peptides
EA199800109A1 (ru) Производные азетидинона для лечения атеросклероза
ATA89792A (de) Neue pleuromutilinderivate, ihre verwendung und verfahren zu ihrer herstellung
GR3019767T3 (en) Method for specific determination of pancreatic alpha-amylase
WO2006085978A3 (en) Conjugates of a cephalosporin derivative and a fluorophor precursor and related compounds as substrates for beta-lactamase gene expression
ATE171936T1 (de) Salpetersäureester von 2-(2,6-dihalophenylamino) phenylacetoessigsäurederivaten und verfahren zu ihrer herstellung
ATE116991T1 (de) Semisynthetische rhodomycine, verfahren zu ihrer herstellung und ihre verwendung als zytostatika.
ES8303434A1 (es) Procedimiento para la obtencion de amidas del ester de acido fosforico (fosfonico).
PT98699A (pt) Processo de acidos acilaminometanofosfonicos e de acidos acilaminometil-fosfinicos
ATE84780T1 (de) Neue di(meth)acrylate, verfahren zu deren herstellung und deren verwendung.
EP0802194A3 (de) Thioürazil-Derivate und diese enthaltende Metall-Oberflächebehandlungsmittel
AU5640286A (en) Intermediates for organophosphate insecticides
IE812876L (en) Ethers of substituted hydroxymethylpyrazines
GR3017838T3 (en) Amines showing fungicidal activity.
DE59300004D1 (de) 2,3-Dihydroxychinoxalinverbindungen.
ATE80882T1 (de) (ethylenedioxo-3,3 zyclohexyl)-4 aketophenon und derivate davon, verfahren zu deren herstellung und verwendung dieser verbindungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties